Effects of Cynanchum wilfordii on osteoporosis with inhibition of bone resorption and induction of bone formation

Lee,Haesu; Kim,Mi  Hye; Choi,You  Yeon; Hong,Jongki; Yang,Woong  Mo

doi:10.3892/mmr.2017.8309

Effects of Cynanchum wilfordii on osteoporosis with inhibition of bone resorption and induction of bone formation

Authors:
- Haesu Lee
- Mi Hye Kim
- You Yeon Choi
- Jongki Hong
- Woong Mo Yang
View Affiliations

Affiliations: Department of Convergence Korean Medical Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea
Published online on: December 19, 2017 https://doi.org/10.3892/mmr.2017.8309
Pages: 3758-3762

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cynanchum wilfordii Hemsley has been used for the treatment of musculoskeletal diseases in traditional Republic of Korean medicine. The present study investigated the effects of C. wilfordii water extract (CW) on postmenopausal osteoporosis. Female mice were used and randomly assigned into a normal group and three ovariectomized (OVX) groups: OVX with vehicle (OVX + vehicle); OVX with 17β‑estradiol (E2; 10 µg/kg/day); and OVX with CW (1 mg/kg/day). Oral administration of CW or E2 intraperitoneal injection began 9 weeks after OVX and continued for 3 weeks. Following sacrifice, bone histology, bone mineral density (BMD) and bone mineral content (BMC) of the femur were observed. Serum osteocalcin concentration was analyzed. In addition, the expression levels of osteoprotegerin (OPG) and osterix were evaluated in human osteoblast‑like Saos‑2 cells. In the lateral and medial epicondyles of the CW‑administrated group, dense and well‑formed bone marrow cells with reduced bone marrow pores were observed. CW decreased the number of tartrate resistant acid phosphatase‑positive multinucleated osteoclasts. BMD and BMC were increased following increased serum osteocalcin levels by CW treatment. The expression levels of OPG and osterix were upregulated by CW treatment in vitro. The results suggested that C. wilfordii has an advantageous effect on osteoporosis and possesses the potential to be used in osteoporosis treatment.

View Figures

View References

1	Cooper C, Campion G and Melton LJ III: Hip fractures in the elderly: A world-wide projection. Osteoporos Int. 2:285–289. 1992. View Article : Google Scholar : PubMed/NCBI
2	Melton LJ III, Chrischilles EA, Cooper C, Lane AW and Riggs BL: Perspective. How many women have osteoporosis? J Bone Miner Res. 7:1005–1010. 1992. View Article : Google Scholar : PubMed/NCBI
3	Holroyd C, Cooper C and Dennison E: Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab. 22:671–685. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zallone A: Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci. 1068:173–179. 2006. View Article : Google Scholar : PubMed/NCBI
5	Nelson HD, Humphrey LL, Nygren P, Teutsch SM and Allan JD: Postmenopausal hormone replacement therapy: Scientific review. JAMA. 288:872–881. 2002. View Article : Google Scholar : PubMed/NCBI
6	Ishida Y and Kawai S: Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi osteoporosis prevention study. Am J Med. 117:549–555. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ross RK, Paganini-Hill A, Wan PC and Pike MC: Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst. 92:328–332. 2000. View Article : Google Scholar : PubMed/NCBI
8	Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petitti D: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 85:304–313. 1995. View Article : Google Scholar : PubMed/NCBI
9	McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK and Lewiecki EM: Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday. Am J Med. 126:13–20. 2013. View Article : Google Scholar : PubMed/NCBI
10	Russell RG and Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. Bone. 25:97–106. 1999. View Article : Google Scholar : PubMed/NCBI
11	Udell JA, Fischer MA, Brookhart MA, Solomon DH and Choudhry NK: Effect of the women's health initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res. 21:765–771. 2006. View Article : Google Scholar : PubMed/NCBI
12	Banu J, Varela E and Fernandes G: Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev. 70:22–40. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lee BJ and Lee K: Discrimination and proper use of polygoni multiflori radix, cynanchi wilfordii radix, and cynanchi auriculati radix in Korea: A descriptive review. Evid Based Complement Alternat Med. 2015:8273802015. View Article : Google Scholar : PubMed/NCBI
14	Choi DH, Lee YJ, Kim JS, Kang DG and Lee HS: Cynanchum wilfordii ameliorates hypertension and endothelial dysfunction in rats fed with high fat/cholesterol diets. Immunopharmacol Immunotoxicol. 34:4–11. 2012. View Article : Google Scholar : PubMed/NCBI
15	Lee HS, Choi JH, Kim YE, Kim IH, Kim BM and Lee CH: Effects of the cynanchum wilfordii ethanol extract on the serum lipid profile in hypercholesterolemic rats. Prev Nutr Food Sci. 18:157–162. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shan L, Liu RH, Shen YH, Zhang WD, Zhang C, Wu DZ, Min L, Su J and Xu XK: Gastroprotective effect of a traditional Chinese herbal drug ‘Baishouwu’ on experimental gastric lesions in rats. J Ethnopharmacol. 107:389–394. 2006. View Article : Google Scholar : PubMed/NCBI
17	Kim MS, Baek JH, Park JA, Hwang BY, Kim SE, Lee JJ and Kim KW: Wilfoside K1N isolated from Cynanchum wilfordii inhibits angiogenesis and tumor cell invasion. Int J Oncol. 26:1533–1539. 2005.PubMed/NCBI
18	Chang A, Kwak BY, Yi K and Kim JS: The effect of herbal extract (EstroG-100) on pre-, peri-and post-menopausal women: A randomized double-blind, placebo-controlled study. Phytother Res. 26:510–516. 2012. View Article : Google Scholar : PubMed/NCBI
19	Compston J: Clinical and therapeutic aspects of osteoporosis. Eur J Radiol. 71:388–391. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hui SL, Slemenda CW and Johnston CC Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 81:1804–1809. 1988. View Article : Google Scholar : PubMed/NCBI
21	Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J and Vogt TM: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 341:72–75. 1993. View Article : Google Scholar : PubMed/NCBI
22	Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW and Riggs BL: Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 8:1227–1233. 1993. View Article : Google Scholar : PubMed/NCBI
23	Teitelbaum SL: Bone resorption by osteoclasts. Science. 289:1504–1508. 2000. View Article : Google Scholar : PubMed/NCBI
24	Suda T, Nakamura I, Jimi E and Takahashi N: Regulation of osteoclast function. J Bone Miner Res. 12:869–879. 1997. View Article : Google Scholar : PubMed/NCBI
25	Harada S and Rodan GA: Control of osteoblast function and regulation of bone mass. Nature. 423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
26	Kirstein B, Chambers TJ and Fuller K: Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem. 98:1085–1094. 2006. View Article : Google Scholar : PubMed/NCBI
27	Minkin C: Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 34:285–290. 1982. View Article : Google Scholar : PubMed/NCBI
28	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
29	Hauschka PV, Lian JB, Cole DE and Gundberg CM: Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiol Rev. 69:990–1047. 1989. View Article : Google Scholar : PubMed/NCBI
30	Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC and Meunier PJ: Serum bone Gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1:1091–1093. 1984. View Article : Google Scholar : PubMed/NCBI
31	Stein GS, Lian JB, Van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY and Pockwinse SM: Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene. 23:4315–4329. 2004. View Article : Google Scholar : PubMed/NCBI
32	Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR and de Crombrugghe B: The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 108:17–29. 2002. View Article : Google Scholar : PubMed/NCBI